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Background. Vascular endothelial growth factor (VEGF)
and its receptors have been implicated in the pathogenesis of
diabetic nephropathy. The objective of this study was to deter-
mine whether alterations of the plasma and urinary VEGF and
sFLT-1 levels were related to the stages and risk factors of dia-
betic nephropathy. In addition, we also examined the regulation
of the VEGF/sFLT-1 expression by various stimuli in cultured
human proximal tubule cells (HPTC).
Methods. A total of 107 type 2 diabetic patients and 47 healthy
control subjects were studied. The expression and protein lev-
els of VEGF and sFLT-1 were measured by semiquantitative
reverse transcription-polymerase chain reaction (RT-PCR) and
enzyme-linked immunosorbent assay (ELISA).
Results. The urinary VEGF and sFLT-1 excretions were sig-
nificantly increased in the microalbuminuric and proteinuric
diabetic patients. The urinary VEGF levels were positively cor-
related with the urinary albumin to creatinine ratio (ACR), uri-
nary sFLT-1 levels, and negatively correlated with creatinine
clearance. The urinary sFLT-1 levels also showed a positive
relationship with the urinary ACR. In cultured HPTC, high
glucose stimuli rapidly up-regulated VEGF synthesis without
having any effect on sFLT-1 synthesis. Interestingly, angiotensin
II (Ang II) induced a dose-dependent increase in the synthesis
of both VEGF and sFLT-1, which was significantly blocked by
losartan.
Conclusion. The urinary excretion of VEGF and sFLT-1 in-
creased at a relatively early stage in diabetic nephropathy as-
sociated with urinary albumin excretion. A marked increase
in both VEGF/sFLT-1 synthesis in response to Ang II was
observed in HPTC, which was different from the response
to glucose stimuli. These findings may imply that VEGF and
sFLT-1 can actively take part in the pathogenesis of diabetic
nephropathy.
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It has been suggested that the vascular endothelial
growth factor (VEGF) system plays a role in the develop-
ment of diabetic renal injury. In the diabetic kidney, the
expression level of this normally expressed VEGF pro-
tein can be markedly increased from the early stages of
diabetic nephropathy, both in type 1 and type 2 diabetic
animal models [1, 2]. In addition, the expression of VEGF
receptors was found to be up-regulated in the kidneys of
diabetic rats [1].
More direct evidence of VEGF being a potential me-
diator of diabetic nephropathy was obtained from the re-
sults of a study using VEGF antibodies. Treatment of the
VEGF antibody was shown to ameliorate both the clas-
sical early features of diabetic kidney disease and more
important, late renal changes (i.e., basement membrane
thickening), with a tendency to reduce the total mesangial
volume in type 2 experimental models [3].
On the other hand, VEGF has been implicated as a
survival factor for endothelial cells and is thought to
play an important role in renal vasculogenesis. Con-
ditional VEGF gene inactivation or administration of
VEGF antagonists during the early postnatal period
impairs the renal vascular development [4, 5]. In addi-
tion, a single intravenous infusion of anti-VEGF anti-
bodies and soluble VEGF receptor (sFLT-1) into normal
healthy mice resulted in excessive albumin excretion in
the urine, via massive glomerular endothelial cell detach-
ment/damage and suppression of the glomerular epithe-
lial slit diaphragm apparatus-associated protein, nephrin
[6]. Collectively, these data suggest that VEGF plays
an important role in maintaining the integrity of the
glomerular filtration barrier.
A naturally occurring soluble form of VEGF receptor-
1, which is an alternately spliced variant of FLT-1 lack-
ing the transmembrane and cytoplasmic domains, acts
as a potent VEGF antagonist [7]. Regarding the role of
VEGF as a potential mediator of diabetic nephropathy
and sFLT-1 as an antagonist of VEGF, we investigated
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whether variations in the VEGF and sFLT-1 levels in the
plasma and urine are related to the severity of diabetic
nephropathy in type 2 diabetic patients. We also inves-
tigated the relationship between the VEGF and sFLT-1
levels and the known risk factors of diabetic nephropathy.
Furthermore, we investigated the expressions of VEGF
and sFLT-1 mRNA and protein, in response to high glu-
cose and angiotensin II (Ang II) in human proximal
tubule cells (HPTC), in order to assess the possible role
of the VEGF/sFLT-1 system in diabetic nephropathy.
METHODS
A total of 107 type 2 diabetic patients and 47 healthy
control subjects were enrolled in this study. All patients
were seen at a metabolic disease outpatient clinic and
were recruited over a period of 3 months. The control
subjects were chosen from among the subjects involved
in an epidemiologic study, which was conducted in Ansan
City, Kyungki-Do in South Korea in 1998 and 1999 [8].
Out of a total of 2000 subjects that received blood and
urinary tests, 47 age- and gender-matched control subjects
were chosen who had no known disease history and no
abnormal laboratory findings.
The diagnosis of type 2 diabetes mellitus was made
according to the Report of the Expert Committee on
the Diagnosis and Classification of Diabetes Mellitus [9].
The patients had to fulfill three additional criteria for in-
clusion in this study: no episodes of ketoacidosis and no
ketonuria, insulin therapy (if any) had to have been initi-
ated at least 5 years after the disease was first diagnosed.
Patients with nondiabetic or obstructive kidney diseases,
abnormal urinary sediment, urinary tract infection, or a
past history of glomerulonephritis or nephroureterolithi-
asis, dilated renal pelvis, or severe atrophied kidney(s)
(either uni- or bilateral on ultrasonography), and patients
with azotemia (serum creatinine >141.8 lmol/L), acute
or severe chronic liver disease, acute inflammatory dis-
eases, hematologic diseases, neoplastic diseases, or who
were pregnant were also excluded. Lifestyle and oral hy-
poglycemic or/and insulin therapy remained unchanged
during the study. Ethical approval was obtained from dis-
trict ethical committees and written informed consent
was obtained from all study subjects.
After the subjects had rested in the sitting position for
at least 5 minutes, their blood pressure was measured with
an appropriately sized cuff placed on the right upper arm.
Hypertension was defined as a systolic pressure ≤140 mm
Hg or a diastolic pressure ≥90 mm Hg or reported treat-
ment with antihypertensive medications. Sixty-seven
diabetic patients and three control subjects had hyperten-
sion. All of the hypertensive diabetic patients were be-
ing treated with antihypertensive medications, and 53 of
these 67 patients were taking an angiotensin-converting
enzyme (ACE) inhibitor or an Ang II receptor antago-
nist with or without other antihypertensive medications.
The other 14 patients, who were not receiving a renin-
angiontensin system (RAS) blockade, were being treated
with calcium channel blockers or alpha or beta blockers.
Diabetic patients were taking antidiabetic drugs, such as
sulfonylurea, metformin, a-glucosidase inhibitor, thiazo-
lidinedione, and insulin. The proportion that had been
assigned to these drugs was similar among these three
groups.
Venous blood was taken from all subjects after
overnight fasting. Fasting blood glucose and postpran-
dial 2-hour glucose were measured using the hexoki-
nase method. Total protein, albumin, blood urea nitrogen
(BUN), creatinine, total cholesterol, triglyceride, and
high-density lipoprotein (HDL) cholesterol were also
measured. Hemoglobin A1c (HbA1c) was measured by
high-performance liquid chromatography (HPLC). The
24-hour urine samples were collected during 3 consecu-
tive days and centrifuged at 3000g for 10 minutes. Urinary
albumin excretion was measured by radioimmunoassay
(Immunotech, Fraha, Czech Republic), at a sensitivity of
0.5 mg/L. The interassay coefficients of variation at 2.17
and 91.2 mg/L were 6.9% and 10%, respectively. Uri-
nary creatinine was measured in the same sample by us-
ing the modified Jaffe´ method. In order to adjust for the
variabilities of urine collection, we calculated the urinary
albumin to creatinine ratio (ACR) in each sample. The
study subjects were divided into four groups: a nondia-
betic healthy control group with a normal ACR (N = 47),
a normoalbuminuric diabetic group with a urinary ACR
<30 lg/mg creatinine in two or more urine samples and
no more than one value ≥30 lg/mg creatinine (N = 37),
a microalbuminuric diabetic group with a urinary ACR
in the range 30 to 299 lg/mg creatinine in at least two
urine samples (N = 37), and an overt proteinuria group,
which contained proteinuric diabetic patients, defined as
having an ACR ≥300 lg/mg creatinine (N = 33). The
microalbuminuric and overt proteinuric groups together
constituted the diabetic nephropathy group. Creatinine
clearance was calculated using the method of Cockcroft
and Gault, as follows: [140 − age (years)] × [lean body
weight (kg)]/72 × serum creatinine (mg/dL). This value
was multiplied by 0.85 for women and by 1.0 for men.
Determination of VEGF and sFLT-1 levels in plasma and
urine
To determine the plasma VEGF and sFLT-1 levels,
8 mL of venous blood was collected, using ethylene-
diaminetetraacetic acid (EDTA) as an anticoagulant,
and immediately centrifuged at 4000g for 10 minutes.
Plasma and urinary samples were aliquoted and stored at
−70◦C until required for testing. VEGF and sFLT-1 levels
were measured by quantitative sandwich enzyme-linked
immunosorbent assay (ELISA) using a commercial kit
(Quantikine) (R&D Systems, Minneapolis, MN, USA)
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for VEGF measurement and ReliaTech GmbH (Braun-
schweig, Germany) for sFLT-1 measurement, according
to the manufacturer’s instructions. This VEGF assay was
specific for the most common VEGF isoform, VEGF165.
The sVEGF-R1 ELISA Kit was specific for the soluble
human VEGF receptor-1. Before undertaking the study,
the assay was validated for plasma and urine samples.
Appropriate reductions in determined VEGF and sFLT-
1 levels were observed by serially diluting both plasma
and urine samples. The assay was performed in duplicate
and the results were expressed as means. Urinary VEGF
levels were measured as described previously [10]. We
also examined the stability of VEGF and sFLT-1 in urine,
particularly the stability in acidic versus nonacidic urine,
and no difference was found between them. The detection
limit of the VEGF assay was 5 pg/mL, its coefficients of
variation for intra-assay precision at 53.7 pg/mL was 6.7%
and interassay precision at 64.5 pg/mL was 8.8%. The
sFLT-1 assay had a minimum sensitivity of 50 pg/mL, an
intra-assay coefficient of variation of 3.7% and an interas-
say coefficient of variation of 8.8% at 10 ng/mL. These
ELISA results showed no cross-reactivity with other cy-
tokines or growth factors. To control for urine concen-
tration differences, the urinary VEGF and sFLT-1 levels
were expressed relative to the urinary creatinine content,
and expressed as VEGF (pg/mg creatinine) and sFLT-1
(ng/mg creatinine).
Immortalized HPTC culture
Human kidney-2 cells, which are an immortalized prox-
imal tubular epithelial cell line from the normal adult
human kidney, were obtained from the American Tis-
sue Culture Collection (Rockville, MD, USA). The cells
were cultivated in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 medium supplemented with 5% heat-
inactivated fetal bovine serum (FBS), 100 U/mL peni-
cillin, 100 lg/mL streptomycin, 2 mmol/L L-glutamine,
5 ng/mL sodium selenite and 5 lg/mL transferrin, 5 pg/
mL thyroxine(T3), 5 ng/mL hydrocortisone, 5 pg/mL
prostaglandin E1 (PGE1), and 10 ng/mL epidermal
growth factor (EGF). The cells in the fifth through the
seventh passages were used in this experiment.
Experimental design
The subconfluent cell monolayers were cultured
in serum- and growth factor-free media containing
5 mmol/L D-glucose and 1% FBS for 48 hours and, then,
the experimental groups were divided into several sub-
groups depending on the stimuli employed. The normal
glucose group used confluent cell monolayers cultured
with 5 mmol/L of D-glucose, while the high glucose group
used 30 mmol/L of D-glucose. We used mannitol as an
osmotic control containing 5 mmol/L of D-glucose and
25 mmol/L of mannitol. In the group involving Ang II
stimulation, Ang II was added to the culture media at fi-
nal concentrations of 1 nmol/L and 10 nmol/L. To define
the role of the angiotensin type 1 (AT1) receptor in Ang
II or high glucose-mediated VEGF and sFLT-1 expres-
sion, losartan (1 and 10 lmol/L), a specific inhibitor of
AT1 receptor, was added 1 hour before Ang II or high
glucose treatment. All of the experimental groups were
cultured in triplicates and harvested at 6, 24, and 72 hours
for extraction of the total RNA and protein. To avoid any
confounding effects resulting from the serum and growth
factors on VEGF and sFLT-1 synthesis, all experiments
were performed in serum- and growth factor-free media.
Expression of VEGF and sFLT-1 mRNA using
semiquantitative reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA extraction was performed with a Trizol
reagent and the cDNA was synthesized by a reverse
transcription reaction using an RNA PCR Kit (Applied
Biosystems, Roche Inc., Foster City, CA, USA) in a 20 lL
mixture containing 1 lg RNA, 50 mmol/L KCl, 10 mmol/L
Tris/HCl, 5 mmol/L MgCl2, 1 mmol/L of each deoxynu-
cleoside triphosphate (dNTPs), oligo-(dT) primers, 20 U
of RNAse inhibitor, and 50 U of Moloney murine
leukemia virus (MuLV) reverse transcriptase. The reac-
tion mixture was incubated for 60 minutes at 42◦C, and
then heated at 90◦C for 7 minutes in a thermocycler
(GeneAmp PCR system 9600) (Perkin Elmer, Roche
Molecular System, Branchburg, NJ, USA). Next, cDNA
was amplified using 2.5 U of AmpliTaq polymerase in
a 25 lL reaction volume containing 10 mmol/L Tris-HCl
(pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 0.2 mmol/L
dNTP, and 40 pmol of each primer. Sequence specific
primers for VEGF, designed according to the human
sequence that detects all three VEGF transcripts, were
used for the PCR reaction. The nucleotide sequences of
each primer were as follows: sense 5′-CCT GGT GGA
CAT CTT CCA GGA GTA CC-3′ and antisense 5′-CTC
ACC GCC TCG GCT TGT CA-3′. The nucleotide se-
quences of sFLT-1 were as follows; sense 5′-CCA GGA
ATG TAT ACA CAG G-3′ and antisense 5′-CAA CAA
ACA CAG AGA AGG-3′. As an internal control, b-
actin was also amplified and the nucleotide sequence for
the primers were as follows: sense 5′-CCC CAG GCA
CCA GGG CGT GAT-3′ and antisense 5′-GGT CAT
CTT CTC GCG GTT GGC CTT GGG GT-3. The PCR
conditions were 40 cycles (VEGF and b-actin) or 30 cy-
cles (sFLT-1) of denaturation at 94◦C for 1 minute, an-
nealing at 58◦C (sFLT-1) or 60◦C (VEGF and b-actin)
for 1 minute, and extension at 72◦C for 3 minutes. The
number of PCR cycles selected represents a point before
the plateau of amplification products, as described previ-
ously [10]. To confirm the identity of each PCR product,
each of the electrophoresed PCR bands was extracted
with a DNA extraction kit (Qiagen, Valencia, CA, USA)
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Table 1. Clinical characteristics of control and diabetic patients according to urinary albumin to creatinine ratio (ACR)
Control Normoalbuminuria Microalbuminuria Proteinuria
Number 47 37 37 33
Age years 55.5 ± 13.6 55.8 ± 12.1 55.7 ± 12.7 55.9 ± 11.8
Gender male/female 17/30 15/22 16/21 14/19
Body mass index kg/m2 24.0 ± 3.63 23.8 ± 2.48 25.5 ± 3.22 24.3 ± 3.41
Duration of diabetes years 7.78 ± 6.29 10.6 ± 7.0 17.0 ± 8.75a
Fasting plasma glucose mmol/L 5.87 ± 1.06b 8.47 ± 2.49 10.16 ± 3.56c 11.17 ± 6.48c
Hemoglobin A1c% 6.94 ± 1.32d 8.04 ± 2.05 8.26 ± 2.40
Total cholesterol mmol/L 4.77 ± 0.97 4.95 ± 0.87 5.53 ± 1.02c 4.97 ± 1.28
Triglyceride mmol/L 1.46 ± 0.84 1.89 ± 1.04 2.67 ± 1.16c 2.67 ± 0.48c
High-density lipoprotein cholesterol mmol/L 1.19 ± 0.40 1.10 ± 0.33 1.27 ± 0.78 1.12 ± 0.31
Systolic blood pressure mm Hg 118.8 ± 13.9b 129.6 ± 17.2 127.0 ± 18.4 136.7 ± 16.7c
Diastolic blood pressure mm Hg 76.3 ± 9.61 80.6 ± 12.8 76.6 ± 11.5 81.3 ± 13.0
Creatinine lmol/L 70.05 ± 18.62 78.03 ± 24.83 93.99 ± 31.03 120.6 ± 46.99e
Creatinine clearance mL/min 102.9 ± 22.9 97.1 ± 26.1 98.2 ± 37.9 81.4 ± 30.8c
Data are numbers or mean ± SD.
aP < 0.05 vs. normo- and microalbuminuria; bP < 0.001 vs. diabetic patients; cP < 0.05 vs. control and normoalbuminuria; dP < 0.05 vs. microalbuminuria and
proteinuria; eP < 0.05 vs. control, normo-, and microalbuminuria.
and sequenced using an ABI automated DNA sequenc-
ing system (ABI Genetic Analyzer 310) (Prism, Branch-
burg Park, NJ, USA). The RT-PCR products were sepa-
rated on a 2% agarose gel with ethidium bromide stain-
ing by electrophoresis. After scanning at 300 dpi, densit-
ometric analysis was performed for quantification using
NIH Image Analysis Software (version 1.61). The VEGF
and sFLT1 mRNA levels were corrected by means of
b-actin. In the case of VEGF, its mRNA expression is
shown as the mean value of the various VEGF isoforms
(VEGF189, VEGF165, VEGF121).
Measurement of VEGF and sFLT-1 protein in culture
supernatant
After exposure to the different culture media, the
cell culture supernatant was removed, and immediately
centrifuged for 15 minutes at 12,000 rpm, before being
stored at −70◦C until required for testing. The VEGF
and sFLT-1 levels were measured by quantitative ELISA
using the aforementioned kit, according to the manu-
facturer’s instructions. Briefly, the various samples used
for VEGF and sFLT-1 measurement were incubated in
a 96-well plate, precoated with a capture antibody di-
rected against VEGF and sFLT-1, for 2 hours. The wells
were then washed three times and incubated with a sec-
ondary antibody against VEGF and sFLT-1 conjugated
to horseradish peroxidase for an additional 2 hours. The
plates were then washed again three times, a substrate
solution containing H2O2 and tetramethylbenzidine was
added, and the optical density was determined at 450 nm.
The protein levels were calculated using a standard curve
derived from known concentrations of the respective re-
combinant proteins.
Statistical analysis
For parametrically distributed data, we used the Stu-
dent unpaired t tests and analysis of variance (ANOVA)
to compare the quantitative variables, and the chi-square
test to compare proportions. The VEGF and sFLT-1 lev-
els were positively skewed with a high frequency of low
values. Because data transformation would not have nor-
malized this distribution, we used nonparametric sta-
tistical methods. An ANOVA was performed with the
Kruskal-Wallis method for the comparisons between the
four groups. Subsequent pair-wise comparisons were per-
formed using the Mann-Whitney U test with correc-
tions for multiple comparisons. The correlations between
VEGF and sFLT-1 and the clinical parameters were ex-
amined by means of Spearman’s rank correlation and by
step-wise multiple regression analysis. The urinary ACR
was log-transformed before being subjected to regression
analysis, in order for it to be transformed to a normal dis-
tribution. A significance level of 5% was chosen for all
tests (P = 0.05). Statistical analyses were performed us-
ing SPSS for Windows, version 11.0(SPSS, Inc., Chicago,
IL, USA).
RESULTS
Clinical characteristics
Table 1 shows the clinical characteristics of the study
population. The average age, gender ratio, and body mass
index were similar in all of the groups. The control group
showed lower fasting plasma glucose, systolic blood pres-
sure, total cholesterol, and creatinine levels than the dia-
betic groups. Among the diabetic patients, those in the
overt proteinuria group had diabetes longer, and had
higher fasting plasma glucose, systolic blood pressure,
creatinine, and HbA1c levels than the normo- and mi-
croalbuminuria groups. The creatinine clearance level in
the overt proteinuria group was lower than that in the
other groups.
VEGF and sFLT-1 levels in plasma and urine
The urinary VEGF concentrations were significantly
higher in the diabetic groups than in the control
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Table 2. Vascular endothelial growth factor (VEGF) plasma and urinary levels according to the stage of diabetic nephropathy
Control Normoalbuminuria Microalbuminuria Proteinuria
Median Interquartile range Median Interquartile range Median Interquartile range Median Interquartile range
Plasma VEGF pg/mL 14.3 48.0 9.9 18.2 16.4 22.9 14.2 23.3
Urinary VEGF pg/mg 27.8 49.0 77.6a 89.0 130.8a,b 191.0 245.0a,c,d 1048.4
creatinine
Plasma sFLT-1 ng/mL 0.11 0.25 0.16 0.28 0.21 0.35 0.2 0.24
Urinary sFLT-1 ng/mg 0.05 0.21 0.15 0.31 0.21e 0.24 0.18e 0.25
creatinine
aP < 0.001 vs. control; bP < 0.05 vs. normoalbuminuria; cP < 0.001 vs. normoalbuminuria; dP < 0.05 vs. microalbuminuria; eP < 0.01 vs. control.
Table 3. Vascular endothelial growth factor (VEGF) plasma and urinary levels according to the presence of hypertension in type 2 diabetic
patients
Without hypertension With hypertension
Median Interquartile range Median Interquartile range
Plasma VEGFa pg/mL 9.2 18.2 17.4 20.5
Urinary VEGFa pg/mg creatinine 104.8 109.9 154.3 263.8
Plasma sFLT-1 ng/mL 0.20 0.31 0.20 0.24
Urinary sFLT-1 ng/mg creatinine 0.20 0.35 0.16 0.19
aP < 0.05 between two groups.
group, even at the normoalbuminuric stage (median
VEGF/creatinine normoalbuminuria 77.6 pg/mg creati-
nine vs. control 27.8 pg/mg creatinine) (P < 0.001). In the
diabetic patients, the urinary VEGF levels were higher in
the microalbuminuria group than in the normoalbumin-
uria group (130.8 pg/mg creatinine vs. 77.6 pg/mg crea-
tinine) (P = 0.024), and higher in the proteinuria group
than in the microalbuminuria group (245.0 pg/mg crea-
tinine vs. 130.8 pg/mg creatinine) (P = 0.021). However,
the plasma VEGF levels were similar in the four groups.
The urinary sFLT-1 excretion levels were also higher
in the microalbuminuria and proteinuria groups than in
the control and normoalbuminuric groups (median sFLT-
1/creatinine microalbuminuria 0.21 ng/mg creatinine vs.
control 0.05 ng/mg creatinine) (P = 0.002) (proteinuria
0.18 ng/mg creatinine vs. control 0.05 ng/mg creatinine)
(P = 0.002). However, the plasma sFLT-1 levels did not
differ among the four groups (Table 2).
Regarding the relationship between hypertension and
the VEGF and sFLT-1 levels in the diabetic patients,
both the plasma and urinary VEGF levels were higher
in the hypertensive patients than in the normotensive pa-
tients [median plasma VEGF 17.4 pg/mL vs. 9.2 pg/mL)
(P = 0.022), urinary VEGF/creatinine 154.3 pg/mg creati-
nine vs. creatinine vs. 104.8 pg/mg creatinine (P = 0.047)]
(Table 3). No differences in the plasma or urinary sFLT-1
levels were observed as a function of the hypertension
status. All of the hypertensive patients were receiving an-
tihypertensive medications, and in 79% of these patients,
the medication was RAS blockade based. No significant
differences were observed between those patients being
treated and those not being treated with RAS blockade-
based medication.
Table 4. Multiple regression analysis urinary albumin to creatinine
ration (ACR) as a dependent variable in the diabetic patients
Variable Beta ± SE P value
Intercept 2.068 ± 0.277 <0.001
Urinary VEGF/creatinine 0.0033 ± 0.001 <0.001
Creatinine 0.248 ± 0.094 0.025
VEGF is vascular endothelial growth factor.
In all of the study subjects, the urinary VEGF level ap-
peared to be correlated positively with the urinary ACR
(r = 0.476, P < 0.001) and urinary sFLT-1 (r = 0.339,
P = 0.002) levels and negatively with creatinine clear-
ance levels (r = −0.251, P = 0.031). The urinary sFLT-1
level appeared to be positively correlated with the uri-
nary ACR (r = 0.211, P = 0.020) and plasma sFLT-1 (r =
0.256, P = 0.005) levels. No correlations were found be-
tween the VEGF and sFLT-1 levels and the other key
risk factors, including age, duration of diabetes mellitus,
blood pressure, fasting glucose, HbA1c, and lipid profile.
We performed a second correlation analysis using the
urinary ACR and several risk factors, in order to deter-
mine their relationships in the diabetic patients. The uri-
nary ACR was found to be positively correlated with the
urinary VEGF level (r = 0.476, P < 0.001), duration of
diabetes (r = 0.246, P = 0.031), systolic blood pressure
(r = 0.171, P = 0.041), the creatinine level (r = 0.391, P =
0.002), and to be negatively correlated with the creati-
nine clearance level (r = −0.286, P = 0.035). By step-wise
multiple regression analysis, in the diabetic patients, the
urinary ACR as a dependent variable, and the urinary
VEGF and serum creatinine levels were included in the
model (R2 = 77.3%) (Table 4).
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Fig. 1. Effects of high glucose and an-
giotensin II (Ang II) on the vascular endothe-
lial growth factor (VEGF) mRNA expres-
sion in human proximal tubule cells (HPTC).
(A) Representative reverse transcription-
polymerase chain (RT-PCR) reaction show-
ing 275 bp product, which is identical to the
alternatively spliced VEGF121 isoform. In ad-
dition, a second 407 bp product, which cor-
responds to the VEGF165 isoform, and a
third 479 bp product corresponding to the
VEGF189 isoform were also detected. (B)
Densitometric analysis of RT-PCR data. Re-
sults are expressed as a mean optical den-
sity ratio of VEGF189/b-actin, VEGF165/b-
actin, and VEGF121/b-actin. Data shown are
means ± SD. The VEGF gene transcript
was significantly elevated under high glucose
(HG) conditions, with the maximal effect ob-
served after 6 hours of treatment. After treat-
ment with Ang II, VEGF mRNA expres-
sion was significantly increased from 6 hours
to 72 hours, peaking at 24 hours of incu-
bation. Losartan treatment significantly de-
creased the VEGF mRNA expression that
had been up-regulated with Ang II, whereas
it had no effect on this up-regulated VEGF
mRNA expression by high glucose stimuli.
NG is normal glucose. ∗P < 0.05; ∗∗P < 0.001
vs. control; #P < 0.001 vs. group with Ang II
at concentration of 10 nmol/L.
VEGF mRNA and protein expression in cultured HPTC
in response to high glucose and Ang II
The mRNA expression for VEGF rapidly increased
under high glucose conditions, with the maximal effect
being observed after 6 hours of treatment (normal glu-
cose 0.59 ± 0.02 vs. high glucose 0.90 ± 0.08) (P < 0.001).
However, these up-regulations were transient, declining
between 24 hours and 72 hours after treatment, while still
remaining higher than in the controls [24 hours 0.79 ±
0.13 vs. 0.61 ± 0.10 (P < 0.05) and 72 hours 0.78 ± 0.08
vs. 0.59 ± 0.12 (P < 0.05)]. Treatment with D-mannitol
did not increase VEGF expression in the normal glucose
group. The VEGF mRNA expression was increased in an
Ang II concentration-dependent manner after 6 hours of
incubation (1 nmol/L 0.91 ± 0.13 and 10 nmol/L 1.05 ±
0.17 vs. control 0.59 ± 0.02) (P < 0.001). However, the
stimulatory effect of Ang II on the VEGF mRNA levels
was decreased at the baseline level after 72-hour treat-
ment of 1 nmol/L of Ang II, whereas with 10 nmol/L
of Ang II, the VEGF mRNA expression significantly in-
creased from 6 hours to 72 hours, peaking at 24 hours of
incubation as compared with the controls (6 hours 1.05 ±
0.17 vs. 0.59 ± 0.02, 24 hours 1.24 ± 0.10 vs. 0.61 ± 0.10,
and 72 hours 0.93 ± 0.11 vs. 0.59 ± 0.12) (P < 0.001).
The effect of 1 lmol/L of losartan did not show any sig-
nificance on VEGF mRNA expression (data not shown).
However, 10 lmol/L of losartan significantly inhibited the
VEGF mRNA expression induced by 10 nmol/L of Ang II
(6 hours 1.05 ± 0.17 vs. 0.65 ± 0.08, 24 hours 1.24 ± 0.10 vs.
0.87 ± 0.11, 72 hours 0.93 ± 0.11 vs. 0.60 ± 0.09, and Ang
II vs. Ang II + losartan group, respectively) (P < 0.001),
whereas it had no effect on the increased VEGF mRNA
expression induced by high glucose (6 hours 0.90 ± 0.08
vs. 0.86 ± 0.09, 24 hours 0.79 ± 0.13 vs. 0.65 ± 0.13,
72 hours 0.78 ± 0.08 vs. 0.72 ± 0.12, and high glucose vs.
high glucose + losartan group, respectively) (P > 0.05)
(Fig. 1).
In comparison with VEGF mRNA, VEGF protein
synthesis was not evident at the 6-hour incubation of
high glucose. VEGF release under high glucose stimu-
lation showed a significant increment after 24-hour and
72-hour incubation compared with that of the control
[24 hours 18.40 ± 0.20 vs. 6.33 ± 0.12 pg/105 cells/mL)
(P < 0.05) and 72 hours 35.9 ± 0.18 vs. 8.76 ± 0.18 pg/105
Kim et al: Pathogenesis of diabetic nephropathy 173
80
60
40
20
0
6-hour 24-hour 72-hour
VE
G
F 
pr
ot
ei
n 
co
nc
en
tra
tio
n,
pg
/1
05
 c
e
lls
/m
L
*
**
**
**
**
**
#
#
NG
HG (30 mmol/L)
Ang (1 nmol/L)
Ang (10 nmol/L)
HG (30 mmol/L)+Los (10 µmol/L)
Ang (10 nmol/L)+Los (10 µmol/L)
Fig. 2. Effects of high glucose (HG) and an-
giotensin II (Ang II) on the vascular endothe-
lial growth factor (VEGF) protein produc-
tion in human proximal tubule cells (HPTC).
HPTCs were exposed to high glucose or dif-
ferent concentrations of Ang II, with or with-
out losartan, for 6-, 24-, and 72-hour inter-
vals. Secretory VEGF proteins were mea-
sured in culture supernatants using enzyme-
linked immunosorbent assay (ELISA). Se-
cretory VEGF peptides were not increased
with high glucose or Ang II stimulation at
6 hours of incubation. However, significantly
increased VEGF release was found from 24
hours of incubation until 72 hours of incuba-
tion under high glucose and Ang II treatment.
Supplementation of losartan in culture media
decreased the Ang II–induced VEGF protein
production. However, it did not decrease the
high glucose–induced VEGF protein produc-
tion. Data are shown mean ± SD. NG is nor-
mal glucose. ∗P < 0.05; ∗∗P < 0.001 vs. control;
#P < 0.001 vs. group with Ang II at concen-
tration of 10 nmol/L.
cells/mL) (P < 0.001). VEGF protein production upon
the response of Ang II was similar with that of high glu-
cose. VEGF peptide release showed a significant time and
dose-dependent increment after the 24-hour incubation
of 10 nmol/L of Ang II [24 hours 32.44 ± 1.33 vs. 6.33 ±
0.12 pg/105 cells/mL (P < 0.001) and 72 hours (68.1 ±
2.78 vs. 8.76 ± 0.18 pg/105 cells/mL) (P < 0.001). The
VEGF protein release after treatment with losartan at a
concentration of 10 lmol/L was significantly suppressed
after 24 hours and 72 hours incubation compared with the
Ang II–treated group [24 hours 32.44 ± 1.33 vs. 12.32 ±
0.19 pg/105 cells/mL (P < 0.001) and 72 hours 68.1 ± 2.78
vs. 24.27 ± 1.27 pg/105 cells/mL) (P < 0.001)]. However,
losartan had no influence on the increased VEGF protein
production induced by high glucose (24 hours 18.4 ± 0.20
vs. 15.2 ± 1.68, 72 hours 35.9 ± 0.18 vs. 24.3 ± 1.84, and
high glucose vs. high glucose + losartan group, respec-
tively) (P > 0.05) (Fig. 2).
sFLT-1 mRNA and protein expression in cultured HPTC
in response to high glucose and Ang II
Both sFLT-1 mRNA and protein were expressed in
basal conditions in cultured HPTC. Interestingly, high
glucose stimulation did not induce significant changes in
the mRNA and protein expression of sFLT-1. Those cells
exposed to 25 mmol/L D-mannitol showed no difference
in the expression of sFLT-1 mRNA compared with that in
the normal glucose group. It is interesting to note that the
response of HPTC to Ang II was quite different from that
under conditions of glucose stimulation. When different
concentrations of Ang II were added to the cells for a pe-
riod of 6 hours, the level of the sFLT-1 gene transcript was
rapidly increased in an Ang II concentration-dependent
manner (1 nmol/L 0.76 ± 0.04, 10 nmol/L 0.95 ± 0.07
vs. control 0.30 ± 0.01) (P < 0.001). This stimulatory ef-
fect of Ang II decreased at 24 hours until 72 hours, al-
though they still remained significantly higher than that
in the controls [24 hours Ang II at 1 nmol/L 0.73 ± 0.03,
10 nmol/L 0.88 ± 0.06 vs. control 0.29 ± 0.02 (P < 0.05)
and 72 hours 1 nmol/L 0.56 ± 0.04, 10 nmol/L 0.75 ± 0.03
vs. control 0.30 ± 0.03 (P < 0.05)]. At a concentration of
1 lmol/L, losartan did not show any significant effect on
sFLT-1 mRNA expression. However, 10 lmol/L of losar-
tan significantly inhibited the sFLT-1 mRNA expression
induced by 10 nmol/L of Ang II (6 hours 0.95 ± 0.07 vs.
0.43 ± 0.01, 24 hours 0.88 ± 0.06 vs. 0.39 ± 0.02, 72 hours
0.75 ± 0.03 vs. 0.33 ± 0.01, and Ang II vs. Ang II + losartan
group, respectively) (P < 0.001) (Fig. 3).
As in the case of its mRNA expression, sFLT-1 protein
synthesis did not show any significant changes in response
to high glucose stimulation throughout the study period.
sFLT-1 protein release was also significantly increased in
a time and dose-dependent manner by Ang II as com-
pared with the controls (Ang II at 10 nmol/L, 6 hours
27.3 ± 1.96 vs. 12.3 ± 1.01, 24 hours 38.4 ± 2.11 vs. 12.5 ±
1.21, 72-hours 56.3 ± 2.97 vs. 12.38 ± 1.03 pg/105 cells/mL)
(P < 0.001). Treatment with losartan at a concentration
of 10 lmol/L also induced a significant suppression of
sFLT-1 peptide synthesis compared with the Ang II–
treated group (10 nmol/L) (6 hours 27.3 ± 1.96 vs. 7.27 ±
0.66, 24 hours 38.4 ± 2.11 vs. 8.43 ± 0.67, and 72 hours
56.3 ± 2.97 vs. 20.3 ± 1.23pg/105 cells/mL) (P < 0.001).
(Fig. 4)
DISCUSSION
In the present study, urinary VEGF levels were found
to increase in proportion to urinary albumin excretion,
even in the normoalbuminuric stage, compared to that in
the control subjects. Although the urinary sFLT-1 levels
did not increase linearly with increasing urinary albumin
excretion, they were higher in the microalbuminuric and
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Fig. 3. Effects of high glucose (HG) and
angiotensin II (Ang II) on the sFLT-1
mRNA expression in human proximal tubule
cells (HPTC). (A) Representative reverse
transcription- polymerase chain reaction (RT-
PCR) showed an apparent single band of 393
bp of sFLT-1 mRNA transcript. (B) Den-
sitometric analysis of RT-PCR data. Results
are expressed as an optical density ratio of
sFLT-1/b-actin. Data shown are means ± SD.
High glucose stimulation did not induce sig-
nificant changes in the sFLT-1 gene transcript.
However, after treatment with Ang II, sFLT-1
mRNA expression was significantly increased
from 6 to 72 hours, in an Ang II concentration–
dependent manner, peaking at 6 hours of in-
cubation. Losartan treatment significantly de-
creased the sFLT-1 mRNA expression that
had been up-regulated with Ang II. NG is nor-
mal glucose. ∗P < 0.05; ∗∗P < 0.001 vs. control;
#P < 0.001 vs. group with Ang II at concen-
tration of 10 nmol/L.
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Fig. 4. Effects of high glucose (HC) and an-
giotensin II (Ang II) on the sFLT-1 pro-
tein production in human proximal tubule
cells (HPTC). HPTCs were exposed to high
glucose or different concentrations of Ang
II, with or without losartan for 6-, 24-,
and 72-hour intervals. Secretory sFLT-1 pro-
teins were measured in culture supernatants
using enzyme-linked immunosorbent assay
(ELISA). Secretory sFLT-1 peptides were not
increased with high glucose stimulation. Af-
ter Ang II stimulation, significantly increased
sFLT-1 peptide release was found from 6
hours incubation until 72 hours incubation in
a dose- and time-dependent manner. Supple-
mentation of losartan in culture media de-
creased the Ang II–induced sFLT-1 protein
production. Data are shown as mean ± SD.
NG is normal glucose. ∗P < 0.05; ∗∗P < 0.001
vs. control; #P < 0.001 vs. group with Ang II
at a concentration of 10 nmol/L.
proteinuric diabetic patients than in the control subjects
and normoalbuminuric diabetic patients. However, the
plasma VEGF and sFLT-1 levels did not change as a re-
sult of urinary albumin excretion. The urinary VEGF and
serum creatinine levels were the independent factors af-
fecting the urinary ACR.
Although correlations between circulating VEGF lev-
els and albumin excretion ratio were controversial in
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previous reports [11–14], we demonstrated that the uri-
nary VEGF levels increased as the nephropathy stages
advanced, and were strongly correlated with the 24-hour
albumin excretion level. Since the glomerular podocyte
is the major site for renal VEGF synthesis, a large pro-
portion of the increased urinary excretion of VEGF
observed in this study may be of glomerular origin. How-
ever, other renal cells, especially tubular epithelial cells,
can also produce VEGF. Recently, we demonstrated
intense VEGF staining in the tubule compartment, par-
ticularly in the proximal segment, in patients with late
diabetic nephropathy [10]. Therefore, the increased uri-
nary VEGF excretions observed in patients with overt
proteinuria suggest that VEGF originating from renal
tubules contributed to the high level of urinary VEGF.
In the diabetic state, the tubule, particularly the prox-
imal segment, is directly exposed to glomerular ef-
fluents, including glucose, large amounts of protein,
advanced glycation end products, and various cytokines
and growth factors, all of which can induce VEGF syn-
thesis. Additionally, tubular ischemia can result from
increased metabolic demand on the tubules or reduced
peritubular blood flow [15]. In this regard, the S3 segment
of the proximal tubule may be particularly vulnerable to
ischemia, which is a potent inducer of VEGF produc-
tion [16]. Interestingly, VEGF production after hypoxia
is more robust in the proximal tubular epithelial cells than
in the glomerular epithelial cells [17]. In this experiment,
glucose stimuli and Ang II rapidly increased the VEGF
synthesis in proximal tubular epithelial cells. This finding
may provide a clue to understanding why the proximal
tubule participates actively in the regulation of intrarenal
VEGF synthesis.
Several studies have suggested that there is a close rela-
tionship between the RAS and VEGF. Ang II is a potent
stimulus for VEGF synthesis in vascular smooth mus-
cle, cardiac and retinal endothelial, and mesangial cells
[18–21]. In this study, Ang II induced increased VEGF
production in a dose-dependent manner, which was com-
pletely abolished by prior treatment with losartan, a se-
lective AT1 receptor antagonist. This result suggests that
Ang II induced VEGF synthesis via the AT1 receptor in
proximal tubular epithelial cells. Losartan seems to par-
tially inhibit the increased VEGF protein production at
72 hours of incubation with high glucose. However, it did
not reach the significant statistical differences. We did not
verify the hypothesis that VEGF expression is increased
on the response to high glucose by up-regulating Ang II.
At least in HPTC, high glucose may stimulate VEGF syn-
thesis mainly via non-Ang II–dependent pathways. Al-
though we did not explore the associated mechanisms
of this increased VEGF production, high glucose con-
centrations may trigger hypoxia-like alterations in cel-
lular redox status, through an increased flux of glucose
via the sorbitol pathway [22]. Because tissue hypoxia is
a major regulator of VEGF production, hypoxia-like re-
dox imbalance may inappropriately up-regulate VEGF
expression.
Based on this close relation between RAS and VEGF,
we can predict that the patients with RAS blockade have
lower plasma and urinary VEGF levels. On the contrary,
we did not observe any differences in VEGF levels ac-
cording to the antihypertensive medications, including
RAS blockade. These results may be ascribed to the small
number of patients who did not taking RAS blockade
(N = 14). However, it is still possible that VEGF levels
might be reduced if compared with pretreatment samples.
There are many pathways activating VEGF expression,
including high glucose, RAS, hypoxia, several cytokines,
and growth factors [23]. Even if we block one of the
possible pathways affecting VEGF by RAS blockade, it
would not be enough to reduce its concentration in hu-
man plasma and urine.
The clinical impact of this increased expression of
VEGF, caused by high glucose concentrations and Ang
II in proximal tubule cells, is not known. Although it
has been suggested that VEGF acts as a potential me-
diator of glomerular hyperfiltration and albuminuria in
the glomerulus, there is also strong evidence for VEGF
acting as an important endothelial cell angiogenic, sur-
vival, and trophic factor [24]. VEGF therapy reduced the
development of progressive glomerulosclerosis and inter-
stitial fibrosis in the remnant kidney model [25], and it is
possible that the Ang II and high glucose-induced VEGF
production, which was observed in this study, is a com-
pensatory mechanism directed at replacing the damaged
endothelium caused by the diabetic milieu. What effect
of the VEGF produced by proximal tubule cells actually
has on diabetic nephropathy remains unclear because the
renal actions of VEGF remain speculative.
Recently, a soluble variant of VEGFR-1 was reported
to be generated by differential splicing of FLT-1 mRNA
[26]. A high level of expression of sFLT-1 has been
detected in the serum and amniotic fluid of pregnant
women, and excess placental sFLT-1 has been found to
contribute to endothelial dysfunction, hypertension, and
proteinuria in preeclampsia [27, 28]. To the best of our
knowledge, this is the first report demonstrating that
proximal tubule cells can produce sFLT-1 mRNA and
protein. The sFLT-1 mRNA and protein expressions were
increased dose-dependently by Ang II stimulation, and
this increase was completely inhibited by pretreatment
with losartan. It is of interest that high glucose stimuli
did not increase either sFLT-1 mRNA or protein pro-
duction. These results imply that it is hyperglycemia that
induces the VEGF overactivity due to unopposed VEGF
action, whereas Ang II coordinately induces both VEGF
and sFLT-1 expression, which results in a weaker activa-
tion of VEGF compared with that produced by glucose
stimuli. This finding may be a possible cause of milder
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increase of the urinary sFLT-1 than VEGF levels in the
diabetic nephropathy groups.
Urinary sFLT-1 excretion was higher in the diabetic
nephropathy group than in the control and normoalbu-
minuric diabetic groups. Even though the urinary sFLT-1
levels showed a positive correlation with ACR and uri-
nary VEGF, they did not increase linearly through the
different stages of diabetic nephropathy, as was observed
in the case of VEGF. Since we demonstrated that prox-
imal tubule cells produce sFLT-1, at least a part of the
increased urinary sFLT-1 may originate from proximal
tubule cells. The sFLT-1 levels were reported to be lower
in patients with peripheral atherosclerosis [29], and hy-
pertension [30], although the VEGF levels were higher
in these clinical settings. We observed that the plasma
and urinary VEGF levels were also higher in the hyper-
tensive diabetic patients, whereas the sFLT-1 levels were
not increased. The VEGF and sFLT-1 levels had a pos-
itive rather than negative correlation, and their mRNA
and protein expressions also seemed to be increased as
a result of Ang II stimuli. Previous studies were per-
formed mainly in hypertensive patients or subjects with
cardiovascular risk factors, but not in diabetic patients.
Although it is hard to explain these conflicting results
regarding the VEGF/sFLT-1 relationship, it may be that
the VEGF/sFLT-1 system expresses and operates differ-
ently in diabetic patients, as compared to the nondiabetic
population.
Physiologically, VEGF activity is tightly regulated by
sFLT-1. In the case of increased VEGF production and a
lower increase of sFLT-1, as in the present study, the rel-
atively unopposed action of VEGF may lead to VEGF
overactivity in the kidney. In other words, in both in vivo
and in vitro studies, these increased VEGF levels have
been ascribed to the defense mechanism, which is de-
signed to protect the kidney from various harmful stim-
uli, including sFLT-1. More studies are needed to define
the highly controversial roles of VEGF and sFLT-1 in the
development and progression of diabetic nephropathy.
CONCLUSION
The present study demonstrated for the first time that
high ambient glucose and Ang II induced the expression
of VEGF and sFLT-1 mRNA and protein in the HPTC.
Although its precise action is obscure, the proximal renal
tubule seems to participate in the regulation of VEGF
synthesis. In addition, urinary VEGF has been shown to
be well correlated with urinary albumin excretion, and
its expression level is increased in the relatively early
stages of diabetic nephropathy. Our study suggests that
the abnormal regulation of the VEGF/sFLT-1 system in
proximal tubular epithelial cells may contribute to the
progression of diabetic nephropathy.
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